Akebia Therapeutics, Inc. Stock

Equities

AKBA

US00972D1054

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:34:22 2024-04-16 am EDT 5-day change 1st Jan Change
1.385 USD -0.36% Intraday chart for Akebia Therapeutics, Inc. -9.42% +12.50%
Sales 2024 * 189M Sales 2025 * 171M Capitalization 291M
Net income 2024 * -63M Net income 2025 * -63M EV / Sales 2024 * 1.54 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.7 x
P/E ratio 2024 *
-4.79 x
P/E ratio 2025 *
-4.85 x
Employees 167
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.79%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Akebia Therapeutics, Inc.

1 day-4.79%
1 week-9.15%
Current month-24.04%
1 month-18.24%
3 months-10.32%
6 months+53.20%
Current year+12.10%
More quotes
1 week
1.39
Extreme 1.39
1.62
1 month
1.39
Extreme 1.39
2.48
Current year
1.21
Extreme 1.21
2.48
1 year
0.59
Extreme 0.5895
2.48
3 years
0.24
Extreme 0.241
4.33
5 years
0.24
Extreme 0.241
13.71
10 years
0.24
Extreme 0.241
31.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 13-06-30
Chief Administrative Officer - 22-03-31
Chief Operating Officer 45 12-12-31
Members of the board TitleAgeSince
Director/Board Member 64 18-12-11
Chairman 73 18-12-11
Director/Board Member 65 21-02-15
More insiders
Date Price Change Volume
24-04-16 1.395 +0.36% 1 729 786
24-04-15 1.39 -4.79% 3,897,726
24-04-12 1.46 -4.58% 4,105,836
24-04-11 1.53 -1.92% 3,154,704
24-04-10 1.56 +1.30% 5,435,326

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT

More quotes
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.39 USD
Average target price
5 USD
Spread / Average Target
+259.71%
Consensus